Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
flutemetamol (18F)
GE Healthcare AS
V09AX04
flutemetamol (18F)
Diagnostic radiopharmaceuticals
Radionuclide Imaging; Alzheimer Disease
This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
Revision: 16
Authorised
2014-08-22
32 B. PACKAGE LEAFLET 33 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VIZAMYL 400 MBQ/ML SOLUTION FOR INJECTION flutemetamol ( 18 F) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your nuclear medicine doctor who will supervise your procedure. - If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What VIZAMYL is and what it is used for 2. What you need to know before VIZAMYL is used 3. How VIZAMYL is used 4. Possible side effects 5. How VIZAMYL is stored 6. Contents of the pack and other information 1. WHAT VIZAMYL IS AND WHAT IT IS USED FOR VIZAMYL contains the active substance flutemetamol ( 18 F) and is used to help diagnose Alzheimer’s disease and other causes of memory loss. This medicine is a radiopharmaceutical product for diagnostic use only. VIZAMYL is used to help diagnose Alzheimer’s disease and other causes of memory loss. It is given to adults with memory problems before they undergo a type of brain scan called a positron-emission tomography (PET) scan. This scan, along with other brain function tests, can help your doctor determine whether or not you may have β-amyloid plaques in your brain. β-Amyloid plaques are deposits sometimes present in the brains of people with dementias (such as Alzheimer’s disease). You should discuss the results of the test with the doctor that requested the scan. The use of VIZAMYL involves exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed to these small amounts of radiation. 2. WHAT YOU NEED TO KNOW BEFORE VIZAMYL IS USED VIZAMYL MUST NOT BE USED: - If you are allergic to flutemetamol ( 18 F) or any of the other ingr Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT VIZAMYL 400 MBq/mL solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for injection contains 400 MBq of flutemetamol ( 18 F) at reference date and time. The activity per vial may range from 400 MBq to 4000 MBq or from 400 MBq to 6000 MBq at the reference date and time. Fluorine ( 18 F) decays to stable oxygen ( 18 O) with a half-life of approximately 110 minutes by emitting a positron radiation of 634 keV, followed by photonic annihilation radiation of 511 keV. Excipients with known effect Each mL of solution contains 55.2 mg of ethanol and 4.1 mg of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless to slightly yellow solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. VIZAMYL is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, see sections 4.4 and 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION A PET scan with flutemetamol ( 18 F) should be requested by clinicians experienced in the clinical management of neurodegenerative disorders. VIZAMYL images should only be interpreted by readers trained in the interpretation of PET images with flutemetamol ( 18 F). A recent co-registered Computed Tomography (CT) scan or Magnetic Resonance (MR) scan of the patient to obtain a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET Lue koko asiakirja